Ranbaxy Laboratories
BSE: 500359 | NSE: RANBAXY | ISIN: INE015A01028 | Pharmaceuticals
Quarterly Results of Ranbaxy Laboratories |
------------------- in Rs. Cr. ------------------- |
 |
|
|
Sep '08 |
Dec '08 |
Mar '09 |
Jun '09 |
Sep '09 |
|
| Sales Turnover |
1,132.82 |
1,012.72 |
822.13 |
1,093.78 |
1,352.46 |
| Other Income |
15.28 |
61.79 |
41.35 |
27.81 |
12.73 |
| Total Income |
1,148.10 |
1,074.51 |
863.48 |
1,121.59 |
1,365.19 |
| Total Expenses |
1,047.36 |
1,292.33 |
1,087.39 |
1,034.41 |
1,065.36 |
| Operating Profit |
85.46 |
-279.61 |
-265.26 |
59.37 |
287.10 |
| Profit On Sale Of Assets |
-- |
-- |
-- |
-- |
-- |
| Profit On Sale Of Investments |
-- |
-- |
-- |
-- |
-- |
| Gain/Loss On Foreign Exchange |
-- |
-- |
-- |
-- |
-- |
| VRS Adjustment |
-- |
-- |
-- |
-- |
-- |
| Other Extraordinary Income/Expenses |
-- |
-- |
-- |
-- |
-- |
| Total Extraordinary Income/Expenses |
-244.14 |
-784.30 |
-918.80 |
806.69 |
-- |
| Tax On Extraordinary Items |
-- |
-- |
-- |
-- |
-- |
| Net Extra Ordinary Income/Expenses |
-- |
-- |
-- |
-- |
-- |
| Gross Profit |
100.74 |
-217.82 |
-223.91 |
87.18 |
299.83 |
| Interest |
361.11 |
206.65 |
13.33 |
-177.49 |
5.90 |
| PBDT |
-504.51 |
-1,208.77 |
-1,156.04 |
1,071.36 |
286.12 |
| Depreciation |
30.26 |
33.75 |
29.01 |
31.54 |
31.68 |
| Depreciation On Revaluation Of Assets |
-- |
-- |
-- |
-- |
-- |
| PBT |
-534.77 |
-1,242.52 |
-1,185.05 |
1,039.82 |
254.44 |
| Tax |
-181.84 |
-435.97 |
-407.27 |
364.37 |
68.36 |
| Net Profit |
-352.93 |
-806.55 |
-777.78 |
675.45 |
186.08 |
| Prior Years Income/Expenses |
-- |
-- |
-- |
-- |
-7.81 |
| Depreciation for Previous Years Written Back/ Provided |
-- |
-- |
-- |
-- |
-- |
| Dividend |
-- |
-- |
-- |
-- |
-- |
| Dividend Tax |
-- |
-- |
-- |
-- |
-- |
| Dividend (%) |
-- |
-- |
-- |
-- |
-- |
| Earnings Per Share |
-- |
-- |
-- |
16.07 |
4.43 |
| Book Value |
-- |
-- |
-- |
-- |
-- |
| Equity |
187.04 |
210.19 |
210.19 |
210.19 |
210.19 |
| Reserves |
-- |
-- |
-- |
-- |
-- |
| Face Value |
5.00 |
5.00 |
5.00 |
5.00 |
5.00 |
|
|
|
|
| Source : Religare Technova |
| Explore Ranbaxy Labs connections |
|
